Industry biotech and pharma scientists often generate evidence that maps well to several EB-1A criteria, particularly original contributions and leading or critical role, but the analysis hinges on how proprietary work, patent records, and clinical contributions are translated into independently corroborated impact.
This page explains how biotech and pharmaceutical research scientists approach the EB-1A extraordinary-ability green card, a self-petition requiring no employer sponsor. Applicants qualify by meeting at least three of ten criteria under 8 C.F.R. § 204.5(h)(3); original contributions of major significance and a leading or critical role are usually the load-bearing criteria, corroborated independently of the employer.
This page is written for industry research scientists in biotech and pharmaceutical companies: principal scientists, senior principal scientists, distinguished scientists, and director-level research scientists at companies including Genentech, Vertex, Moderna, Pfizer, GSK, Regeneron, AstraZeneca, Bristol Myers Squibb, Novartis, Eli Lilly, and at well-regarded biotechs across drug discovery, protein engineering, gene therapy, mRNA platforms, oncology, immunology, and rare disease. We also see candidates from leading nonprofit research institutes (the Broad, Whitehead, Salk, Scripps, Cold Spring Harbor) when their roles look more industry-research than academic.
Two patterns at intake. The first is the senior IC scientist who assumes EB-1A is mostly for academics and undersells industry-leadership evidence, project ownership, regulatory submissions, and named patents. The second is the candidate who overweights any single high-impact paper or patent and underestimates how aggressively current adjudication parses independent corroboration. The exercise we run is the same: an inventory of publications, patents (with prosecution status and licensing or product link), clinical trial roles, internal leadership roles, peer review, and outside recognition, mapped against the criteria before we recommend a path.
EB-1A is sometimes premature for industry scientists in their first three to five years post-PhD, particularly where most contributions are unpublished and patent prosecution is incomplete. We will say so at intake.
External awards relevant here include society honors (for instance, AAPS Fellow, ACS National Award recipients, AAAS Fellow, ASBMB awards), early-career awards from professional societies, named lectureships at academic institutions, and invited keynote selections at major society meetings. Internal company awards are typically discounted, though scientist-of-the-year programs at top-tier companies that are decided by external advisory boards have sometimes been credited. Industry-relevant academic recognition (Pew Scholars, Searle Scholars, Damon Runyon for those who began in academia) carries forward for candidates who later moved to industry. How a particular award is read depends on documented selectivity and the rest of the record.
Open-membership professional societies (ASBMB, AACR, ACS, AAPS at the regular member level) generally do not satisfy this criterion. Selective fellow grades (AAPS Fellow, AAAS Fellow, RSC Fellow at FRSC, ACS Fellow), invited membership in groups such as the American Society for Clinical Investigation, election to the National Academy of Inventors, and similar bodies have supported this criterion in past cases when the selection bylaws and external review process are documented carefully. Whether a particular membership qualifies depends on how the bylaws read against the regulation and the officer's interpretation.
Coverage in outlets such as STAT News, Endpoints News, FierceBiotech, BioPharma Dive, Nature News, Science News, and major newspaper science sections, often tied to a clinical trial readout, an FDA approval, a published paper, or a launch announcement, can support this criterion when it focuses on the candidate's role rather than the company. Press releases and trade-publication republications of company announcements are typically given limited weight. The threshold for "major media" is applied with variability, and officers occasionally discount industry trade press even when its readership is the relevant professional audience.
For industry scientists, this criterion typically draws from peer review for journals (Nature, Cell, Science and field journals such as Nature Biotechnology, Nature Medicine, Cell Metabolism, JACS, Journal of Medicinal Chemistry, Blood, Cancer Cell), grant review for NIH study sections, NSF panels, and disease-foundation review boards (LLS, ALSAC, JDRF, CFF), conference program committee service (AACR, ASH, ASCO, AAPS, ACS national meetings), and external review of academic theses. Editorial board roles at field journals and ad hoc reviewing for top journals tend to read better than volume-driven reviewer counts. Selectivity and stature documentation help more than raw counts.
This is typically the load-bearing criterion for biotech and pharma scientists, and it is also where current adjudication is most aggressive. Strong records tend to combine: named inventorship on patents that became approved drugs or that have been licensed to product-stage development (this is the most persuasive single evidence type we see for industry scientists, when the inventorship contribution and link to the product can be documented), publications in field-flagship journals with independent citation depth, mechanism-of-action discoveries that have shifted clinical or development practice, contributions to platforms (mRNA, CRISPR-based therapeutics, ADC linker chemistry) that other companies have adopted, and named roles in regulatory submissions (INDs, BLAs, NDAs) that resulted in clinical advancement. Independent expert testimony from senior scientists at other companies and academic institutions, addressing field-level impact rather than personal competence, tends to anchor the analysis. The "major significance" determination is openly discretionary.
Industry publication patterns vary widely by company and program stage. Discovery-stage scientists at companies with strong publishing cultures (Genentech, Regeneron, Vertex, Moderna in some areas) often have substantial Nature, Cell, Science, Nature Biotechnology, Nature Medicine, and field-flagship records. Late-stage clinical and CMC scientists may have fewer but more clinically consequential publications (NEJM, Lancet, JAMA for clinical readouts). Last-author convention in life sciences signals senior scientific leadership and we document it carefully. Whether a particular publication record is sufficient on its own depends on the rest of the petition.
This criterion rarely fits industry scientists in the form contemplated by the regulation. Conference posters and oral presentations are typically not "exhibitions," and we generally do not press this criterion. Comparable-evidence framing is sometimes preferable when the record contains unusual public-engagement contributions.
For industry scientists, this criterion is often stronger than candidates initially expect, including for senior IC scientists who hold named project leadership without people management. Roles that have supported this criterion in past cases include named program lead, target lead, asset lead, platform lead, head of a therapeutic area or modality, named inventor on the company's lead clinical program, and leadership of cross-functional CMC, clinical pharmacology, or translational teams. Top-tier biotechs and pharmas, leading nonprofit research institutes (the Broad, Whitehead, Salk, Scripps), and well-regarded mid-cap biotechs are typically presented as distinguished organizations, with documentation of company stature in the relevant therapeutic area or modality. Whether the role is read as critical depends on documented responsibilities, decision authority, and impact on company-level outcomes.
Senior industry scientist compensation, including base, bonus, RSUs, and PSUs, often supports this criterion when benchmarked against the right comparison set (industry research scientists at the equivalent level and geography). Director-level and VP-level scientific compensation typically clears comfortable thresholds. Benchmark choice matters: BLS occupational data alone is rarely sufficient for senior industry scientists, and we typically supplement with industry compensation surveys (Radford, Mercer pharma surveys), executive search data, and proxy statements where titles match. Whether the differential is sufficient depends on the benchmark and the officer.
Does not apply to biotech and pharmaceutical scientists.
These objection patterns are decoded in the RFE Encyclopedia →
You'll hear back within 48 hours whenever a petition is being drafted or an RFE is on the clock. No ghosting.
Every petition is drafted from a fresh interview-extracted fact sheet. We don't recycle petitions or rec letters across unrelated clients.
We file on every criterion we can credibly defend. When a criterion is thin, we fold it into "Original Contributions of Major Significance" rather than stand it up as its own weak argument.
RFE response is a separate flat fee of $2,000 to $5,000, quoted before any work begins. Strategy consultations, whether-to-respond conversations, and post-denial planning are not billed hourly.
We use a structured SOAR (Situation, Obstacle, Action, Result) interview process to understand the client's actual work, including in technical and niche fields where the record doesn't speak for itself.
We draft reference letters from the interview and evidence review — included in the petition fee — then coordinate with recommenders for signature. We don't leave recommenders to produce their own letters.
RFEs aren't surprises. Every petition is drafted with our standing RFE response framework in mind so that if an RFE lands, we're executing a plan, not starting from scratch.
The initial call is a candid read on whether the case is defensible — not a pitch. If we think the profile doesn't support EB-1A right now, we'll tell you.
Tell us about your immigration needs and we'll be in touch to discuss how we can help.
Immigration counsel to Fortune 500 employers at a national firm · Adjudicated 12,000+ visas at the U.S. Consulate, Mexico · Working in U.S. immigration since 2008
Featured in Newsweek, Condé Nast Traveler, Daily Mail